You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

indolent non-Hodgkin lymphoma (iNHL)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023

Non Hodgkin Lymphoma Trial in Australia, United States (Tenalisib,)

Completed
Has Results
  • Non Hodgkin Lymphoma
  • Huntsville, Alabama
  • +11 more
Jul 20, 2021

Lymphoma, Non-Hodgkin Trial in Beijing (Copanlisib (Aliqopa, BAY80-6946))

Completed
  • Lymphoma, Non-Hodgkin
  • Copanlisib (Aliqopa, BAY80-6946)
  • Beijing, China
    Beijing Cancer Hospital
May 17, 2021

Obinutuzumab in Chinese Real-world Patients With iNHL

Not yet recruiting
  • Lymphomas Non-Hodgkin's B-Cell
  • Changzhou, Jiangsu, China
  • +24 more
Jul 23, 2023

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin Trial in France, Italy, Netherlands (Obinutuzumab, CC-122)

Active, not recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Non-Hodgkin
  • Borddeaux Cedex, France
  • +9 more
Nov 11, 2022

Patterns in People With Indolent Non-Hodgkin Lymphoma,Type of

Active, not recruiting
  • Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
  • Copanlisib (BAY80-6946)
  • Multiple Locations, Taiwan
    Many Locations
Jan 31, 2023

Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Follicular Lymphoma Trial in Aichi, Miyagi, Tokyo (Idelalisib)

Completed
Has Results
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Aichi, Japan
  • +2 more
Feb 24, 2021

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma Trial in United States (Rituximab, ALT-803)

Terminated
  • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
  • Rituximab
  • ALT-803
  • Minneapolis, Minnesota
  • +3 more
Feb 11, 2021

Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,

Withdrawn
  • Recurrent Follicular Lymphoma
  • +8 more
  • (no location specified)
Jun 2, 2022

CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)

Terminated
  • CD20-positive Non-Hodgkin Lymphoma
  • Rituximab + MG4101
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Oct 24, 2022

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)

Completed
Has Results
  • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Sep 20, 2022

Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma Trial in Miami, Baltimore, Milwaukee (Zydelig)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • +8 more
  • Miami, Florida
  • +2 more
Apr 21, 2022

Indolent Non-hodgkin Lymphoma Trial in Worldwide (Duvelisib)

Active, not recruiting
  • Indolent Non-hodgkin Lymphoma
  • Washington, District of Columbia
  • +39 more
May 17, 2021

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +23 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 23, 2022

Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2

Active, not recruiting
  • Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
  • +22 more
  • External Beam Radiation Therapy
  • Orbital Radiation
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

Indolent Lymphoma, Low-dose Radiotherapy Trial in Beijing (Low-dose radiotherapy)

Recruiting
  • Indolent Lymphoma
  • Low-dose Radiotherapy
  • Low-dose radiotherapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Sep 13, 2022

Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Trial in United States (TAK-007, Chemotherapy Agents)

Recruiting
  • Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
  • TAK-007
  • Chemotherapy Agents
  • Birmingham, Alabama
  • +18 more
Aug 17, 2022

Inert Non Hodgkin's Lymphoma Trial in Beijing (IBI376, Rituximab)

Recruiting
  • Inert Non Hodgkin's Lymphoma
  • Beijing, China
    Biotherapeutic Department, Chinese PLA General Hospital
Feb 19, 2022

Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

Completed
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2023

Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia Trial in Bergamo (Blinatumomab Expanded T-cells (BET))

Active, not recruiting
  • Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
  • Blinatumomab Expanded T-cells (BET)
  • Bergamo, Italy
    ASST - Papa Giovanni XXIII
Dec 22, 2021

Lymphoma, Non-Hodgkin Trial in Worldwide (Copanlisib (BAY80-6946), Placebo, Rituximab)

Active, not recruiting
  • Lymphoma, Non-Hodgkin
  • Copanlisib (BAY80-6946)
  • +7 more
  • Chandler, Arizona
  • +199 more
Jan 31, 2023

DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

Not yet recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
  • +6 more
  • Bridging radiation therapy
  • +2 more
  • (no location specified)
Jan 4, 2023

Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Seattle (Laboratory Biomarker

Active, not recruiting
Has Results
  • Follicular Lymphoma
  • +2 more
  • Laboratory Biomarker Analysis
  • Pembrolizumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 6, 2022

Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma Trial in United States (NKTR-255, NKTR-255 Q21, Rituximab)

Recruiting
  • Multiple Myeloma
  • +2 more
  • Goodyear, Arizona
  • +16 more
Mar 18, 2022

Severe COVID-19 Infection in CLL or B-NHL Who Received

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
    • (no location specified)
    Apr 6, 2023